What Awaits DNAI On June 6?

(RTTNews) - ProNAi Therapeutics Inc. (DNAI) will be presenting interim results from its phase II trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma at the 52nd Annual Meeting of the American Society of Clinical Oncology on June 6, 2016.

PNT2258, the company's lead product candidate, is designed to target cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer.

Initiated in December 2014, the phase II trial of PNT2258 in relapsed or refractory diffuse large B-cell lymphoma, dubbed Wolverine, is designed to characterize anti-tumor activity and collect safety data on approximately 60 patients. The study is currently recruiting participants.

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, and is of aggressive nature, affecting a type of white blood cells called lymphocytes.

PNT2258 is also being explored in the indication of Richter's Transformation.

A phase II trial for PNT2258 for the treatment of Richter's transformed CCL, dubbed Brighton, initiated last October, is underway.

Richter's transformation is a highly aggressive form of cancer in which chronic lymphocytic leukemia transforms into a fast-growing type of B-cell lymphoma.

The Brighton study is designed to enroll approximately 50 patients with Richter's transformation. The primary endpoint is overall response rate and secondary outcome measures include disease control rate, duration of overall response, time to response, progression-free survival, overall survival and safety.

Founded in 2004, ProNAi Therapeutics went public on The NASDAQ Global Market on July 16, 2015 at a price of $17.00 per share.

At March 31, 2016, the company had zero debt and cash of $140.9 million (Data sourced from Yahoo Finance).

DNAI has thus far hit a low of $4.48 and a high of $33.75. The stock closed Friday's trading at $6.38, down 0.31%. In after hours, the stock was up 6.58% to $6.80.